Targeted Therapies for Hepatocellular Carcinoma
TLDR
Identification of oncogenes that mediate tumor progression, and trials that monitor their products as biomarkers, might lead to personalized therapy; reagents that interfere with signaling pathways required for HCC progression might be used to treat selected populations, and thereby maximize the efficacy and cost benefit.About:
This article is published in Gastroenterology.The article was published on 2011-05-01 and is currently open access. It has received 402 citations till now. The article focuses on the topics: Sorafenib & Targeted therapy.read more
Citations
More filters
Journal ArticleDOI
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle,Alejandro Forner,Josep M. Llovet,Vincenzo Mazzaferro,Fabio Piscaglia,Jean-Luc Raoul,Peter Schirmacher,Valérie Vilgrain +7 more
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer
Josep M. Llovet,Michel Ducreux,Riccardo Lencioni,Adrian M. Di Bisceglie,Jean-Francois J. DuFour,Tim F. Greten,Eric Raymond,Tania Roskams,Vincenzo Mazzaferro,Jordi Bruix,Massimo Colombo,Andrew X. Zhu +11 more
TL;DR: The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data.
Journal ArticleDOI
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
Bruno Sangro,Carlos Gomez-Martin,Manuel de la Mata,Mercedes Iñarrairaegui,Elena Garralda,Pilar Barrera,Jose I Riezu-Boj,Esther Larrea,Carlos Alfaro,Pablo Sarobe,Juan José Lasarte,Jose Luis Perez-Gracia,Ignacio Melero,Ignacio Melero,Jesús Prieto,Jesús Prieto +15 more
TL;DR: Tremelimumab safety profile and antitumor and antiviral activity, in patients with advanced HCC developed on HCV-induced liver cirrhosis, support further investigation.
Journal ArticleDOI
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
TL;DR: In this paper, a review outlines pathogenic mechanisms that seem to be common to both hepatitis B virus and hepatitis C virus and suggest innovative approaches to the prevention and treatment of HCC.
Journal ArticleDOI
Mechanisms of HBV-induced hepatocellular carcinoma
TL;DR: HBV-related HCCs may arise on non-cirrhotic livers, further supporting the notion that HBV plays a direct role in liver transformation by triggering both common and etiology specific oncogenic pathways in addition to stimulating the host immune response and driving liver chronic necro-inflammation.
References
More filters
Journal ArticleDOI
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
Chih-Hung Hsu,Ying-Chun Shen,Zhong-Zhe Lin,Pei-Jer Chen,Yu-Yun Shao,Yea-Hui Ding,Chiun Hsu,Ann-Lii Cheng +7 more
TL;DR: Metronomic chemotherapy with tegafur/uracil can be safely combined with sorafenib and shows preliminary activity to improve the efficacy of sorafinib in advanced HCC patients.
Journal ArticleDOI
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
Tanios Bekaii-Saab,Joseph Markowitz,Nichole Prescott,Wolfgang Sadee,Nyla A. Heerema,Lai Wei,Zunyan Dai,Audrey C. Papp,Angela Campbell,Kristy Culler,Catherine Balint,Bert H. O'Neil,Ruey Min Lee,Mark M. Zalupski,Janet Dancey,Helen X. Chen,Michael R. Grever,Charis Eng,Charis Eng,Miguel A. Villalona-Calero +19 more
TL;DR: Lapatinib is well-tolerated but seems to benefit only a subgroup of patients for whom predictive molecular or clinical characteristics are not yet fully defined, and PTEN, P-AKT, and P70S6K expression did not correlate with survival.
Journal ArticleDOI
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.
Fumihiko Kanai,Haruhiko Yoshida,Ryosuke Tateishi,Shinpei Sato,Takao Kawabe,Shuntaro Obi,Yuji Kondo,Makoto Taniguchi,Kazumi Tagawa,Masafumi Ikeda,Chigusa Morizane,Takuji Okusaka,Hitoshi Arioka,Shuichiro Shiina,Masao Omata +14 more
TL;DR: TSU-68 at a dose of 200 mg bid determined by stratification into liver function, showed promising preliminary efficacy with a high safety profile in patients with HCC who had been heavily pre-treated.
Journal ArticleDOI
Shifting paradigms: the seeds of oncogene addiction
TL;DR: Although the success of imatinib was not a revolution in the Copernican sense, it spawned a transformation in cancer research that has fueled an urgency to characterize cancer genomes comprehensively and discover the driver mutations in all cancers.
Journal ArticleDOI
Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?
TL;DR: The components, main types, and analytic issues of health economic evaluations using studies of cancer interventions as examples are discussed and why members of the cancer community should care about economic analyses are discussed.
Related Papers (5)
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more